CD19 and mantle cell lymphoma: On February 5, 2021, Breyanzi (Lisocabtagene Maralecel) (CD19/FMC63) was approved by FDA, indicated for treating adult patients with R/R LBCL after two or more lines of systemic therapy, including unspecified DLBCL (including TFL), HGBCL, PMBCL and 3B grade FL [79], Approval was based on results from TRANSCEND NHL 001 (NCT02631044), aimed at verifying the efficacy and safety of Breyanzi in R/R LBCL and MCL patients [80].